There are currently 587 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, GSK Investigational Site and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effects of Passive Heat Therapy in Patients With Chronic Kidney Disease
NCT05924919
Recruiting
The objective of this proposal is to investigate the acute effects of whole-body passive heat therapy using far-infrared technology on vascular function, exercise capacity, and renal function in CKD patients. The central hypothesis is that an acute bout of whole-body passive heat therapy will be well-tolerated and lead to acute improvements in large blood vessel (macrovascular) function, small blood vessel (microvascular) function, and exercise capacity without significantly altering markers of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Renal Insufficiency, Chronic
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Local Institution - 0136, Richmond, Virginia
Conditions: Multiple Myeloma
Register for Updates
Preventing Retaliatory Gun Violence in Violently Injured Adults
NCT04813185
Recruiting
The purpose of this research study is to find out if a hospital-based violence intervention (Bridging the Gap) is effective for reducing violence. The researchers think that adults who receive Bridging the Gap will see greater improvements than those who do not receive the intervention. This study will allow them to learn more about the intervention's effectiveness. The study will also help them understand if the violence intervention affects other behaviors, such as firearm use, drug use, aggre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Violence
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk r... Read More
Gender:
Female
Ages:
Between 35 years and 50 years
Trial Updated:
05/01/2024
Locations: VCU Massey Cancer Center at Stony Point, Richmond, Virginia +1 locations
Conditions: Ovarian Carcinoma
Register for Updates
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
NCT05177822
Recruiting
Patients who have a heart attack are at high risk for future development of heart failure ('weakening of the heart'). The researchers believe that the reaction of the heart muscle to injury (inflammation) during a heart attack may be contributing to the risk of heart failure. The current study will test the ability of an anti-inflammatory medicine (anakinra) to block the inflammation in the body during and after a heart attack.
Gender:
All
Ages:
21 years and above
Trial Updated:
05/01/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Heart Failure
Register for Updates
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT04408755
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/30/2024
Locations: Clinical Research Site #840-025, Richmond, Virginia
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
Pentoxifylline in Diabetic Kidney Disease
NCT03625648
Recruiting
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Diabetic Kidney Disease
Register for Updates
Improving Traumatic Brain Injury Rehab Care With Comm Health Services: a Research Project Within the TBI Model System
NCT06188364
Recruiting
TBI rehabilitation care transitions refer to the processes of preparing patients, families, and community-based healthcare providers for the patient's passage from inpatient rehabilitation to the home and community or to another level of care. Persons with TBI have heterogenous neurological impairment (cognitive and behavioral foremost, along with motor, sensory, and balance), that limits their functional independence and participation, and increases their risk for secondary medical conditions,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Traumatic Brain Injury
Register for Updates
Defining Endpoints in Becker Muscular Dystrophy
NCT05257473
Recruiting
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD)
Gender:
Male
Ages:
6 years and above
Trial Updated:
04/29/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Register for Updates
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/29/2024
Locations: GSK Investigational Site, Richmond, Virginia
Conditions: Asthma
Register for Updates
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
NCT04120493
Recruiting
This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized, multicenter, multiple dose, double-blind, imitation surgery, first-in-human (FIH) study. Cohort 3 participants will receive either high or low dose (1:1 randomization). Participants enrolled in Cohort 3 will also receive an immunosuppression regimen consisting of dexamethasone, sirolimus, and rituximab.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
04/29/2024
Locations: Virginia Commonwealth University VCU School of Medicine, Department of Neurology, Richmond, Virginia
Conditions: Huntington's Disease
Register for Updates
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy
NCT04829539
Recruiting
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Virginia Cancer Institute, Richmond, Virginia +2 locations
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates